0.09%QQQQ 50.01 0.08%MSFT 29.99 
1.51%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
Mylan Inc. manufacturer of generic pharmaceutical products said on Thursday an extended first quarter loss and a large increase on its revenue triggered by the purchase of Merck KGaA in October.
| MYL | 12.22 |  0.25 |
The company reported a net loss of $443.9 million or $1.46 a share compared to $71.3 million or 31 cents a share the previous year due to special charges.
However its revenue more than doubled to $1.07 billion from $487.3 million helped by an increase on sales overseas.
Earnings were 9 cents a share excluding unusual items surpassing forecasts of 8 cents a share on revenue of $1.13 billion.
Shares of the pharmaceutical company slumped 2.73 percent at the end of Thursday composite trading to $12.46 a share in the New York stock Exchange. In after hours trading shares fell to $12.27.
Eritrea is considering five more applications for exploration licences, and will make its decision within the year.
A Swiss pilot strapped on a jet-powered wing and leaped from a plane Wednesday f...
The One Laptop Per Child project is about to find out whether Microsoft Corp., a...
|
Find the most up to date research from leading investment firms to make the most informed investing decisions
Professional Website Design For Corporate - Get a Free Quote Today
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
